65.16 +0.32 (0.49%)
Pre-Market: 6:05AM EST
|Bid||64.22 x 900|
|Ask||65.57 x 1400|
|Day's Range||64.30 - 66.74|
|52 Week Range||64.27 - 89.54|
|Beta (3Y Monthly)||1.40|
|PE Ratio (TTM)||53.81|
|Earnings Date||Feb 4, 2019 - Feb 8, 2019|
|Forward Dividend & Yield||2.28 (3.48%)|
|1y Target Est||86.97|
Bristol-Myers (BMY) gets positive opinion from the CHMP on the label expansion of Sprycel. The company also collaborates with other institutions for developing pipeline.
Big biotech stocks (GILD) (ticker: GILD) and (BIIB) (BIIB) were moving in opposite directions Tuesday, driven by analyst commentary. Where we were: It has been a difficult year for biotech stocks in general. Both Gilead and Biogen have notched losses larger than the broader market’s.
Puma Biotech (PBYI) reports positive top-line data from the phase III NALA study, conducted on its breast cancer drug Nerlynx in third-line setting.
Experimental new drugs at critical stages of development could soon send these stocks screaming in one direction or another.
Shares of Johnson & Johnson (NYSE:JNJ) have fallen below their 200-day moving average to return to levels not seen since August, down nearly 13% from the highs seen in early December. Analysts are looking for earnings of $1.95 per share on revenues of $20.2 billion. Gilead Sciences (NASDAQ:GILD) shares are down 16% from the highs set in early October, a double-top high that now sets up a possible violation of the May lows that would put the mid-2017 levels near $60 in play — which would be worth a 10% drop from current levels.
While millennials will soon overtake them in sheer number, boomers require extensive medical care. Theoretically, this trend should boost Big Pharma stocks. If pharmaceutical stocks represent viability, they’re doing a bad job of it.
While firms like Goldman Sachs have hailed 2019 as “the year of NASH” with late-stage data expected from Gilead Sciences Inc. and Intercept Pharmaceuticals Inc., other analysts say the first study results will only scratch the surface. “There’s part of the market that thinks 2019 is the year for NASH. NASH, or nonalcoholic steatohepatitis, is a significant form of chronic liver disease that affects both adults and children and can require a liver transplant.
Gilead Sciences Inc., AT&T Inc., British American Tobacco PLC and Lloyds Banking Group PLC have declined to their respective 3-year lows
AMAG inks a deal to buy Perosphere Pharmaceuticals, which will add the latter's investigational candidate, ciraparantag, to its portfolio.
There are some biotech stocks which are down more than 20% this year so far but have the potential to bounce back next year.
NEW YORK, NY / ACCESSWIRE / December 14, 2018 / U.S. markets finished modestly higher on Thursday as investors continue to worry about trade tensions between the U.S. and China. The Dow Jones Industrial ...
The Zacks Analyst Blog Highlights: Gilead Sciences, Conatus Pharmaceuticals, Biogen, Ionis Pharmaceuticals and Exelixis
The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen
Despite their well-publicized fall from grace, several marijuana stocks have stabilized from their severe correction. Whether it’s political unrest in the Middle East, the spiraling protests in Paris or the ugly Huawei controversy, marijuana for now is mostly a North American issue. Second, medical cannabis potentially offers significant social utility.
How's Seattle Genetics Positioned? For fiscal 2018 and 2019, Seattle Genetics’ gross margins are expected at 88.54% and 88.58%, respectively, as compared with gross margins of 88.78% for fiscal 2017. In comparison, the fiscal 2018 gross margins of peers Amgen (AMGN), Gilead Sciences (GILD), and Eli Lilly & Co (LLY) are expected at 85.83%, 84.81%, and 76.05%, respectively.